November 4, 2025 – Qingdao Baheal Medical INC. (Stock Code: 301015.SZ) today announced it has entered into an expanded collaboration with global biotechnology leader CSL to strengthen their presence in China’s plasma-derived therapies sector. Under the agreement, Baheal Medical will hold exclusive promotion, marketing, and distribution rights for CSL’s albumin product Alburex® in specified markets within mainland China. This partnership builds upon the companies’ initial retail market cooperation established in 2018 and aims to fully integrate CSL’s globally leading plasma-derived therapies with Baheal’s professional commercialization platform. The move is designed to better serve the growing demand for high-quality plasma-derived products in China and expand patient access.

Signing Ceremony 

Albumin, a critical plasma-derived product, is widely used in emergency volume replacement, severe hypoalbuminemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, and as supportive therapy in cardiopulmonary bypass and plasmapheresis. It serves as a therapeutic lifeline in critical and emergency care. In China, the plasma-derived therapies sector is regarded as a “high-value segment” within biopharma due to stringent regulatory controls and limited supply.

As the largest therapeutic drug category in China by market size, albumin exceeds RMB 30 billion in annual sales, with imported products historically dominating the market. CSL, with nearly four decades of presence in China, is one of the country’s key suppliers, accounting for approximately 24% of the market. Given China’s large population and accelerating aging trend, clinical demand for albumin remains strong and continues to grow. According to Frost & Sullivan, the therapeutic albumin market in China is projected to reach RMB 57 billion by 2030, with a compound annual growth rate of 6.0% from 2025 to 2030. In 2024, imported albumin products recorded a 17% year-on-year increase in batch releases, accounting for nearly 70% of the market.

CSL’s albumin is developed and manufactured under globally consistent and rigorous quality standards, supported by extensive international clinical evidence. Its clinical value and safety profile are widely recognized by the global medical community. Alburex® is specifically designed for the Chinese market, with a key differentiator being its ability to be stored at temperatures up to 30°C, protected from light. This significantly reduces dependency on complex cold-chain logistics, enhancing both accessibility and supply chain resilience. This feature offers healthcare institutions at all levels a more convenient and cost-effective storage solution while ensuring stable supply and reliable treatment for patients when it matters most.

The partnership is expected to generate strong synergies in liver disease management. China has a substantial patient population with liver disease, among whom cirrhotic ascites is a common and serious complication. As albumin is a cornerstone therapy in this setting, market demand continues to rise. Baheal Medical has established robust commercial capabilities and a mature distribution network in hepatology, underpinned by its leading anti-fibrosis brand, Fuzheng Huayu. With liver disease positioned as a strategic therapeutic area for both companies, this collaboration will help deliver more integrated and valuable treatment solutions for patients.

“As a critical therapy for severely ill patients, albumin serves broad patient needs in China. With nearly 40 years of commitment to this market, albumin remains a strategic product for CSL in China,” said Wang Yu, General Manager of CSL China. “We are dedicated to deepening local partnerships and expanding our reach across China’s vast and varied channels. We are pleased to have already improved the accessibility of albumin in China alongside Baheal Medical and look forward to leveraging their mature commercial platform to unlock further market potential—broadening and deepening albumin coverage to enhance the quality of life for critically ill patients in China and support the ‘Healthy China 2030’ vision.”

Fu Gang, Chairman of Baheal Pharma Group, stated, “Baheal is a technology-driven pharmaceutical company with a systematic, globally minded presence in innovative drugs and radiotherapy. Since 2018, we have maintained a long-term, stable partnership with CSL. Our mission to ‘improve healthcare through technological innovation’ aligns closely with CSL’s patient-centric values. We look forward to continuing our collaboration to ensure albumin products serve clinical needs in China more precisely and efficiently, creating lasting value for patients’ health and quality of life.”

Baheal Medical’s innovation pipelines now span multiple core therapeutic areas, including oncology and critical care, fibrotic diseases, and bone health. Supported by forward-looking R&D strategy and professional commercialization capabilities, Baheal Medical will continue to enrich its product matrix and advance the adoption of more high-quality medical and health products. As a leader in China’s albumin market, CSL remains committed to advancing clinical practice through medical innovation, high-quality academic initiatives, and clinical exchange programs—empowering physicians with evidence-based guidance on the appropriate use and optimal application of albumin to improve outcomes for patients with critical illnesses in China.

Looking ahead, both companies will leverage this partnership to promote the standardization, professionalization, and high-quality development of China’s plasma-derived therapies market, while exploring further synergies across therapeutic areas—ultimately benefiting patients nationwide.

Reference:

1. Moshang Consulting. China Pharmaceutical Market Analysis Report H2 2023–H1 2024.

2. Southwest Securities. *2024 Plasma-Derived Products Industry Tracking Report (Including Batch Release Data)*.

3. Frost & Sullivan Analysis. Market Size and Forecast for Human Serum Albumin Therapeutics in China, 2016–2030E.